IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

Summary

This trial is an open-label, multicenter, first-in-human dose-escalation and cohort expansion Phase I/II clinical study to evaluate the safety, tolerability and preliminary efficacy of IMM2902 in the treatment of HER2-expressing advanced solid tumors

Timeline

Start

2022-02-15

Primary completion

2024-10

Completion

2024-10

Drugs

Indications